Search

Your search keyword '"Seidman, Andrew"' showing total 641 results
Start Over Author "Seidman, Andrew"
641 results on '"Seidman, Andrew"'

1. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

Author

Berger, Michael, Bromberg, Jacqueline, Chen, Linda, Dang, Chau, Das, Jeeban P, Drullinsky, Pamela, Eng, Julianna, Flynn, Jessica, Gelblum, Daphna Y, Gillespie, Erin F, Girshman, Jeffrey, Gomez, Daniel R, Gucalp, Ayca, Guttmann, David, Hajj, Carla, Higginson, Daniel, Iqbal, Afsheen, Khan, Atif J, LaPlant, Quincey, Lee, Nancy Y, Mann, Justin M, Modi, Shanu, Namakydoust, Azadeh, Ng, Kenneth, Patel, Juber, Powell, Simon N, Preeshagul, Isabel, Reis-Filho, Jorge S, Reyngold, Marsha, Riaz, Nadeem, Rimner, Andreas, Robson, Mark E, Rudin, Charles M, Sanford, Rachel, Seidman, Andrew D, Shah, Ronak, Shaverdian, Narek, Shepherd, Annemarie F, Shin, Jacob Y, Sugarman, Steven, Traina, Tiffany A, Tsai, Chiaojung Jillian, Wu, Abraham J, Xu, Amy J, Yang, Jonathan T, Yeh, Randy, Zhang, Zhigang, Zhi, Wanqing, Eng, Juliana, Seidman, Andrew, and Traina, Tiffany

Published
2024
Full Text
View/download PDF

12. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

Author

Tripathy, Debu, Tolaney, Sara M, Seidman, Andrew D, Anders, Carey K, Ibrahim, Nuhad, Rugo, Hope S, Twelves, Chris, Dieras, Veronique, Müller, Volkmar, Tagliaferri, Mary, Hannah, Alison L, and Cortés, Javier

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Neurosciences, Clinical Trials and Supportive Activities, Breast Cancer, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Brain Neoplasms, Breast Neoplasms, Female, Heterocyclic Compounds, 4 or More Rings, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Polyethylene Glycols, Progression-Free Survival, Topoisomerase I Inhibitors, brain metastases, chemotherapy, etirinotecan pegol, metastatic breast cancer, NKTR-102, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. Motivated by improved survival findings from subgroup analyses from the Phase III BEACON trial, this ongoing randomized, Phase III trial compares etirinotecan pegol to drugs commonly used for advanced breast cancer in patients with stable, treated breast cancer brain metastases who have been previously treated with an anthracycline, taxane and capecitabine. The primary end point is overall survival. Secondary end points include objective response rate, progression-free survival and time to CNS disease progression or recurrence in patients with/without CNS lesions present at study entry. Trial registration number: NCT02915744.

Published
2019

16. Evolving HER2+ Metastatic Breast Cancer Landscape

Author

Seidman, Andrew D., Bardia, Aditya, Pegram, Mark, and Rao, Ruta

Subjects
Metastasis -- Care and treatment, Antineoplastic agents, Breast cancer -- Care and treatment, Antimitotic agents, Health
Abstract

HER2-positive metastatic breast cancer has historically been considered a difficult-to-treat disease given that it is often more aggressive than other breast cancers. However, several recently established targeted treatment options that [...]

Published
2021

25. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

Author

Tsai, Chiaojung Jillian, Yang, Jonathan T, Shaverdian, Narek, Patel, Juber, Shepherd, Annemarie F, Eng, Juliana, Guttmann, David, Yeh, Randy, Gelblum, Daphna Y, Namakydoust, Azadeh, Preeshagul, Isabel, Modi, Shanu, Seidman, Andrew, Traina, Tiffany, Drullinsky, Pamela, Flynn, Jessica, Zhang, Zhigang, Rimner, Andreas, Gillespie, Erin F, Gomez, Daniel R, Lee, Nancy Y, Berger, Michael, Robson, Mark E, Reis-Filho, Jorge S, Riaz, Nadeem, Rudin, Charles M, Powell, Simon N, Berger, Michael, Bromberg, Jacqueline, Chen, Linda, Dang, Chau, Das, Jeeban P, Drullinsky, Pamela, Eng, Julianna, Flynn, Jessica, Gelblum, Daphna Y, Gillespie, Erin F, Girshman, Jeffrey, Gomez, Daniel R, Gucalp, Ayca, Guttmann, David, Hajj, Carla, Higginson, Daniel, Iqbal, Afsheen, Khan, Atif J, LaPlant, Quincey, Lee, Nancy Y, Mann, Justin M, Modi, Shanu, Namakydoust, Azadeh, Ng, Kenneth, Patel, Juber, Powell, Simon N, Preeshagul, Isabel, Reis-Filho, Jorge S, Reyngold, Marsha, Riaz, Nadeem, Rimner, Andreas, Robson, Mark E, Rudin, Charles M, Sanford, Rachel, Seidman, Andrew D, Shah, Ronak, Shaverdian, Narek, Shepherd, Annemarie F, Shin, Jacob Y, Sugarman, Steven, Traina, Tiffany A, Tsai, Chiaojung Jillian, Wu, Abraham J, Xu, Amy J, Yang, Jonathan T, Yeh, Randy, Zhang, Zhigang, and Zhi, Wanqing

Abstract

Most patients with metastatic cancer eventually develop resistance to systemic therapy, with some having limited disease progression (ie, oligoprogression). We aimed to assess whether stereotactic body radiotherapy (SBRT) targeting oligoprogressive sites could improve patient outcomes.

Published
2024
Full Text
View/download PDF

29. Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases

Author

Sambade, Maria J., Prince, Grace, Deal, Allison M., Trembath, Dimitri, McKee, Megan, Garrett, Amy, Keith, Kevin, Ramirez, Juanita, Midkiff, Bentley, Blackwell, Kimberly, Sammons, Sarah, Leone, Jose Pablo, Brufsky, Adam, Morikawa, Aki, Brogi, Edi, Seidman, Andrew, Ewend, Matthew, Carey, Lisa A., Moschos, Stergios J., Hamilton, Ronald L., Vincent, Benjamin, and Anders, Carey

Published
2019
Full Text
View/download PDF

30. Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.

Author

Chew, Sonya, primary, Ferraro, Emanuela, additional, Chen, Yuan, additional, Barrio, Andrea Veronica, additional, Kelly, Daniel W., additional, Modi, Shanu, additional, Seidman, Andrew David, additional, Wen, Hannah Yong, additional, Brogi, Edi, additional, Robson, Mark E., additional, and Dang, Chau T., additional

Published
2023
Full Text
View/download PDF

31. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Author

Lazaratos, Anna-Maria, primary, Maritan, Sarah M., additional, Quaiattini, Andrea, additional, Darlix, Amelie, additional, Ratosa, Ivica, additional, Ferraro, Emanuela, additional, Griguolo, Gaia, additional, Guarneri, Valentina, additional, Pellerino, Alessia, additional, Hofer, Silvia, additional, Jacot, William, additional, Stemmler, Hans-Joachim, additional, van den Broek, Marcel P.H., additional, Dobnikar, Nika, additional, Panet, Francois, additional, Lahijanian, Zubin, additional, Morikawa, Aki, additional, Seidman, Andrew D., additional, Soffietti, Riccardo, additional, Panasci, Lawrence, additional, Petrecca, Kevin, additional, Rose, April A.N., additional, Bouganim, Nathaniel, additional, and Dankner, Matthew, additional

Published
2023
Full Text
View/download PDF

33. Long‐term stability of respiratory sinus arrhythmia among adults with and without a history of depression.

Author

Seidman, Andrew J., Bylsma, Lauren M., Yang, Xiao, Jennings, J. Richard, George, Charles J., and Kovacs, Maria

Subjects
*SINUS arrhythmia, *HEART beat, *PARASYMPATHETIC nervous system, *INTRACLASS correlation, *ROOT-mean-squares
Abstract

Respiratory sinus arrhythmia (RSA) is an index of parasympathetic nervous system activity reflecting respiratory influences on heart rate. This influence is typically measured as high frequency heart rate variability (HF‐HRV) or root mean square of successive differences (RMSSD) of adjacent inter‐beat intervals. Examining the long‐term stability of its measurement is important as levels of resting RSA have been conceptualized as a marker of individual differences; in particular, of an individual's autonomic regulation and affect‐related processes, including emotion regulation. At present, it is not known if resting RSA levels reflect stable differences over a long‐term period (i.e., >1 year). Even less is known about how RSA stability differs as a function of depression history and whether it relates to depression risk trajectories. In the present study, we examined the 1.5‐year test–retest reliability of resting RSA using the intraclass correlation coefficient (ICC) in 82 adults: n = 41 with a history of depression (ever‐depressed); n = 41 controls with no depression history (never‐depressed). HF‐HRV was fairly stable in both groups (ever‐depressed ICC = 0.55, never‐depressed ICC = 0.54). RMSSD was also fairly stable in ever‐depressed adults (ICC = 0.57) and never‐depressed controls (ICC = 0.40). ICC values for both indices did not differ between groups per overlapping 95% confidence intervals. Therefore, RSA stability as assessed by both frequency (HF‐HRV) and time domain (RMSSD) measures was not attenuated by a depression history. Implications and the need for future research are discussed. Researchers commonly utilize resting levels of parasympathetically‐mediated heart rate variability (e.g., HF‐HRV, RMSSD) to assess emotion regulation in healthy and clinical samples, particularly depression. However, little is known about its long‐term stability, and even less so in the presence of psychopathology. Our findings indicate that resting HF‐HRV and RMMSD are fairly stable indices of RSA over a period of 1.5 years, on average, among adults with and without a history of depression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Data from Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases

Author

Morikawa, Aki, primary, de Stanchina, Elisa, primary, Pentsova, Elena, primary, Kemeny, Margaret M., primary, Li, Bob T., primary, Tang, Kendrick, primary, Patil, Sujata, primary, Fleisher, Martin, primary, Van Poznak, Catherine, primary, Norton, Larry, primary, and Seidman, Andrew D., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Data from Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases

Author

Morikawa, Aki, primary, de Stanchina, Elisa, primary, Pentsova, Elena, primary, Kemeny, Margaret M., primary, Li, Bob T., primary, Tang, Kendrick, primary, Patil, Sujata, primary, Fleisher, Martin, primary, Van Poznak, Catherine, primary, Norton, Larry, primary, and Seidman, Andrew D., primary

Published
2023
Full Text
View/download PDF

40. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Author

Lazaratos, Anna-Maria, Maritan, Sarah M, Quaiattini, Andrea, Darlix, Amélie, Ratosa, Ivica, Ferraro, Emanuela, Griguolo, Gaia, Guarneri, Valentina, Pellerino, Alessia; https://orcid.org/0000-0003-3243-0059, Hofer, Silvia; https://orcid.org/0000-0002-0831-2098, Jacot, William, Stemmler, Hans-Joachim, van den Broek, Marcel P H, Dobnikar, Nika, Panet, Francois, Lahijanian, Zubin, Morikawa, Aki, Seidman, Andrew D, Soffietti, Riccardo; https://orcid.org/0000-0002-9204-7038, Panasci, Lawrence, Petrecca, Kevin, Rose, April A N, Bouganim, Nathaniel, Dankner, Matthew; https://orcid.org/0000-0003-4869-5895, Lazaratos, Anna-Maria, Maritan, Sarah M, Quaiattini, Andrea, Darlix, Amélie, Ratosa, Ivica, Ferraro, Emanuela, Griguolo, Gaia, Guarneri, Valentina, Pellerino, Alessia; https://orcid.org/0000-0003-3243-0059, Hofer, Silvia; https://orcid.org/0000-0002-0831-2098, Jacot, William, Stemmler, Hans-Joachim, van den Broek, Marcel P H, Dobnikar, Nika, Panet, Francois, Lahijanian, Zubin, Morikawa, Aki, Seidman, Andrew D, Soffietti, Riccardo; https://orcid.org/0000-0002-9204-7038, Panasci, Lawrence, Petrecca, Kevin, Rose, April A N, Bouganim, Nathaniel, and Dankner, Matthew; https://orcid.org/0000-0003-4869-5895

Abstract

Background: Patients with HER2+ breast cancer (BC) frequently develop leptomeningeal metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the neoadjuvant, adjuvant, and metastatic settings, including for parenchymal brain metastases, their efficacy for patients with LM has not been studied in a randomized controlled trial. However, several single-armed prospective studies, case series and case reports have studied oral, intravenous, or intrathecally administered HER2-targeted therapy regimens for patients with HER2+ BC LM. Methods: We conducted a systematic review and meta-analysis of individual patient data to evaluate the efficacy of HER2-targeted therapies in HER2+ BC LM in accordance with PRISMA guidelines. Targeted therapies evaluated were trastuzumab (intrathecal or intravenous), pertuzumab, lapatinib, neratinib, tucatinib, trastuzumab-emtansine and trastuzumab-deruxtecan. The primary endpoint was overall survival (OS), with CNS-specific progression-free survival (PFS) as a secondary endpoint. Results: 7780 abstracts were screened, identifying 45 publications with 208 patients, corresponding to 275 lines of HER2-targeted therapy for BC LM which met inclusion criteria. In univariable and multivariable analyses, we observed no significant difference in OS and CNS-specific PFS between intrathecal trastuzumab compared to oral or intravenous administration of HER2-targeted therapy. Anti-HER2 monoclonal antibody-based regimens did not demonstrate superiority over HER2 tyrosine kinase inhibitors. In a cohort of 15 patients, treatment with trastuzumab-deruxtecan was associated with prolonged OS compared to other HER2-targeted therapies and compared to trastuzumab-emtansine. Conclusions: The results of this meta-analysis, comprising the limited data available, suggest that intrathecal administration of HER2-targeted therapy for patients with HER2+ BC LM confers no additional benefit over oral and/or IV treatment regimens. Although the number of

Published
2023

42. Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis

Author

Yang, Jonathan T., primary, Wijetunga, N. Ari, additional, Pentsova, Elena, additional, Wolden, Suzanne, additional, Young, Robert J., additional, Correa, Denise, additional, Zhang, Zhigang, additional, Zheng, Junting, additional, Steckler, Alexa, additional, Bucwinska, Weronika, additional, Bernstein, Ashley, additional, Betof Warner, Allison, additional, Yu, Helena, additional, Kris, Mark G., additional, Seidman, Andrew D., additional, Wilcox, Jessica A., additional, Malani, Rachna, additional, Lin, Andrew, additional, DeAngelis, Lisa M., additional, Lee, Nancy Y., additional, Powell, Simon N., additional, and Boire, Adrienne, additional

Published
2022
Full Text
View/download PDF

49. Phase II randomized study comparing proton craniospinal irradiation with photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis.

Author

Yang, Jonathan T., primary, Wijetunga, N. Ari, additional, Pentsova, Elena, additional, Wolden, Suzanne L., additional, Young, Robert J., additional, Correa, Denise, additional, Zhang, Zhigang, additional, Zheng, Junting, additional, Betof Warner, Allison, additional, Yu, Helena Alexandra, additional, Kris, Mark G., additional, Seidman, Andrew David, additional, Malani, Rachna, additional, Lin, Andrew, additional, DeAngelis, Lisa Marie, additional, Lee, Nancy Y., additional, Powell, Simon N., additional, and Boire, Adrienne Ann, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results